As the plenary session wrapped up and exciting data about new treatments such as daratumumab in multiple myeloma, and other discoveries were presented, a difficult topic cannot be avoided.
Paying for these new innovations. Understanding oncology value frameworks therefore becomes paramount.
Affordability of new treatments and combinations of treatments in oncology continues to challenge the oncology community. As the cost of new cancer drugs approaches the median household income, oncologists must make difficult decisions and consider the enormous and increasing cost of treatment as they evaluate the incremental clinical benefit.
Five independent value frameworks, including the ASCO value framework, have been introduced to address this challenge of competing priorities and resource constraints. Each one asks a different set of questions—yet each is designed to address rising costs, avoid the consequences of unaffordability, ensure access, and build toward equality of cancer care.
Continued development of these tools will guide the oncology community to align with core values.